San Diego, California, USA

Viking Therapeutics

US clinical-stage biotechnology company whose lead candidate, VK2735, is a dual GLP-1 and GIP receptor agonist being developed in injected and oral forms for obesity. VK2735 is an investigational drug and is not approved anywhere. The company reports no product revenue.

VK2735 in Phase 3 (investigational)

Viking's 10-Q states that in June 2025 it announced the start of two Phase 3 studies of the injected form of VK2735, VANQUISH-1 and VANQUISH-2, that enrolment in VANQUISH-1 was completed in November 2025, and that enrolment in VANQUISH-2 was completed in March 2026.[src]

No revenue to date

Viking states it has not generated any revenue since its inception. For the quarter ended June 30, 2026 it reported a net loss of US$128.0 million, and cash, cash equivalents, restricted cash and short-term investments of US$501.9 million at June 30, 2026.[src]

Licence from Ligand for other programs

Viking's 10-K states it obtained exclusive worldwide rights to its VK2809, VK0214 and VK5211 programs under a master license agreement with Ligand Pharmaceuticals dated May 2014.[src]